{"id":"https://openalex.org/W7204486947","doi":"https://doi.org/10.1093/neuonc/noag172.046","title":"18 TTFields with maintenance temozolomide/pembrolizumab versus TTFields with maintenance temozolomide/placebo for newly diagnosed glioblastoma: the phase 3 EF-41/KEYNOTE D58 trial","display_name":"18 TTFields with maintenance temozolomide/pembrolizumab versus TTFields with maintenance temozolomide/placebo for newly diagnosed glioblastoma: the phase 3 EF-41/KEYNOTE D58 trial","publication_year":2026,"publication_date":"2026-08-27","ids":{"openalex":"https://openalex.org/W7204486947","doi":"https://doi.org/10.1093/neuonc/noag172.046"},"language":"en","primary_location":{"id":"doi:10.1093/neuonc/noag172.046","doi":"https://doi.org/10.1093/neuonc/noag172.046","is_oa":true,"landing_page_url":"https://doi.org/10.1093/neuonc/noag172.046","pdf_url":"https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.046/70805811/noag172.046.pdf","source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.046/70805811/noag172.046.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084891453","display_name":"Gerben R. Borst","orcid":"https://orcid.org/0000-0002-2102-2722","observed_orcids":["https://orcid.org/0000-0002-2102-2722"]},"institutions":[{"id":"https://openalex.org/I28407311","display_name":"University of Manchester","ror":"https://ror.org/027m9bs27","country_code":"GB","type":"education","lineage":["https://openalex.org/I28407311"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gerben Borst","raw_affiliation_strings":["University of Manchester and The Christie NHS Foundation Trust , Manchester,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Manchester and The Christie NHS Foundation Trust , Manchester,","institution_ids":["https://openalex.org/I28407311","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102739384","display_name":"David Dinh Tran","orcid":"https://orcid.org/0000-0002-2380-8921","observed_orcids":["https://orcid.org/0000-0002-2380-8921"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I4210117038","display_name":"USC Norris Comprehensive Cancer Center","ror":"https://ror.org/01nmyfr60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800154431","https://openalex.org/I4210117038"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David D Tran","raw_affiliation_strings":["Department of Neurological Surgery, Norris Comprehensive Cancer Center, University of Southern California , Los Angeles,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurological Surgery, Norris Comprehensive Cancer Center, University of Southern California , Los Angeles,","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I4210117038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085549922","display_name":"Ashley Parham Ghiaseddin","orcid":"https://orcid.org/0000-0001-5599-4610","observed_orcids":["https://orcid.org/0000-0001-5599-4610"]},"institutions":[{"id":"https://openalex.org/I2800717037","display_name":"University of Florida Health","ror":"https://ror.org/04tk2gy88","country_code":"US","type":"education","lineage":["https://openalex.org/I2800717037","https://openalex.org/I33213144"]},{"id":"https://openalex.org/I33213144","display_name":"University of Florida","ror":"https://ror.org/02y3ad647","country_code":"US","type":"education","lineage":["https://openalex.org/I33213144"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashley P Ghiaseddin","raw_affiliation_strings":["University of Florida Department of Neurosurgery , Gainesville,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Florida Department of Neurosurgery , Gainesville,","institution_ids":["https://openalex.org/I2800717037","https://openalex.org/I33213144"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011340023","display_name":"Michael K. Lim","orcid":"https://orcid.org/0000-0003-0523-3076","observed_orcids":["https://orcid.org/0000-0003-0523-3076"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Lim","raw_affiliation_strings":["Department of Neurosurgery, Stanford University School of Medicine , Palo Alto,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurosurgery, Stanford University School of Medicine , Palo Alto,","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017177249","display_name":"Michael Weller","orcid":"https://orcid.org/0000-0002-1748-174X","observed_orcids":["https://orcid.org/0000-0002-1748-174X"]},"institutions":[{"id":"https://openalex.org/I202697423","display_name":"University of Zurich","ror":"https://ror.org/02crff812","country_code":"CH","type":"education","lineage":["https://openalex.org/I202697423"]},{"id":"https://openalex.org/I4210100468","display_name":"University Hospital Zurich","ror":"https://ror.org/01462r250","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210100468"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Michael Weller","raw_affiliation_strings":["University Hospital and University of Zurich , Zurich,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital and University of Zurich , Zurich,","institution_ids":["https://openalex.org/I202697423","https://openalex.org/I4210100468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074447222","display_name":"Motoo Nagane","orcid":"https://orcid.org/0000-0002-0018-1652","observed_orcids":["https://orcid.org/0000-0002-0018-1652"]},"institutions":[{"id":"https://openalex.org/I190930483","display_name":"Kyorin University","ror":"https://ror.org/0188yz413","country_code":"JP","type":"education","lineage":["https://openalex.org/I190930483"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Motoo Nagane","raw_affiliation_strings":["Kyorin University School of Medicine , Tokyo,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kyorin University School of Medicine , Tokyo,","institution_ids":["https://openalex.org/I190930483"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031998230","display_name":"Jacob C. Easaw","orcid":"https://orcid.org/0000-0001-5270-1050","observed_orcids":["https://orcid.org/0000-0001-5270-1050"]},"institutions":[{"id":"https://openalex.org/I126859394","display_name":"Alberta Health Services","ror":"https://ror.org/02nt5es71","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I126859394"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Jacob C Easaw","raw_affiliation_strings":["Alberta Health Services , Edmonton,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alberta Health Services , Edmonton,","institution_ids":["https://openalex.org/I126859394"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041166804","display_name":"Elizabeth Cohen\u2010Jonathan Moyal","orcid":"https://orcid.org/0000-0002-6593-9276","observed_orcids":["https://orcid.org/0000-0002-6593-9276"]},"institutions":[{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]},{"id":"https://openalex.org/I4405258862","display_name":"Universit\u00e9 de Toulouse","ror":"https://ror.org/01ahyrz84","country_code":"FR","type":"education","lineage":["https://openalex.org/I4405258862"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Elizabeth Cohen-Jonathan Moyal","raw_affiliation_strings":["Universit\u00e9 de Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e9 de Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole , Toulouse,","institution_ids":["https://openalex.org/I4210098740","https://openalex.org/I4405258862"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":14,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5132,"currency":"USD","value_usd":5132},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.65310953,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10874","display_name":"Electromagnetic Fields and Biological Effects","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1304","display_name":"Biophysics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.9649999737739563},{"id":"https://openalex.org/keywords/tumor-treating-fields","display_name":"tumor treating fields","score":0.9549999833106995},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7639999985694885},{"id":"https://openalex.org/keywords/pd-1-pd-l1-blockade","display_name":"PD-1/PD-L1 blockade","score":0.6930000185966492},{"id":"https://openalex.org/keywords/newly-diagnosed-glioblastoma","display_name":"newly diagnosed glioblastoma","score":0.8769999742507935},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8820000290870667},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.875},{"id":"https://openalex.org/keywords/mgmt-promoter-methylation","display_name":"MGMT promoter methylation","score":0.7369999885559082},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.5130000114440918},{"id":"https://openalex.org/keywords/chemoradiotherapy","display_name":"chemoradiotherapy","score":0.6779999732971191}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8881999850273132},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.8851000070571899},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6818000078201294},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6172999739646912},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5922999978065491},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.5224000215530396},{"id":"https://openalex.org/C2776194525","wikidata":"https://www.wikidata.org/wiki/Q282142","display_name":"Glioblastoma","level":2,"score":0.511900007724762},{"id":"https://openalex.org/C2778424827","wikidata":"https://www.wikidata.org/wiki/Q5090613","display_name":"Chemoradiotherapy","level":3,"score":0.5026000142097473},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4219000041484833},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.42080000042915344},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.39890000224113464},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3659000098705292},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.35179999470710754},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.33399999141693115},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.32010000944137573},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.31929999589920044},{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.3122999966144562},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3075999915599823},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.29030001163482666},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.2833000123500824},{"id":"https://openalex.org/C81182388","wikidata":"https://www.wikidata.org/wiki/Q353963","display_name":"Complication","level":2,"score":0.28279998898506165},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.2750000059604645},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.2705000042915344},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.2529999911785126}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1093/neuonc/noag172.046","doi":"https://doi.org/10.1093/neuonc/noag172.046","is_oa":true,"landing_page_url":"https://doi.org/10.1093/neuonc/noag172.046","pdf_url":"https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.046/70805811/noag172.046.pdf","source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13519685","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13519685/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Neuro Oncol","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/neuonc/noag172.046","doi":"https://doi.org/10.1093/neuonc/noag172.046","is_oa":true,"landing_page_url":"https://doi.org/10.1093/neuonc/noag172.046","pdf_url":"https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.046/70805811/noag172.046.pdf","source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.5822330713272095,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Study Protocol","id":"https://openalex.org/study-designs/study-protocol"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7204486947.pdf","grobid_xml":"https://content.openalex.org/works/W7204486947.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Abstract":[0],"Introduction":[1],"With":[2],"the":[3,41,250],"current":[4],"standard-of-care":[5],"for":[6,128,163],"glioblastoma":[7,78,108],"(maximal":[8],"safe":[9],"resection":[10],"followed":[11],"by":[12],"radiotherapy":[13,197],"with":[14,59,90,166,269],"concurrent":[15],"TMZ,":[16],"then":[17],"maintenance":[18,154,261],"temozolomide/TTFields),":[19],"median":[20],"overall":[21],"survival":[22,85],"(OS)":[23],"is":[24,44,96,178,187,204,253],"approximately":[25],"21":[26],"months.":[27],"Immune":[28],"checkpoint":[29],"inhibitors":[30],"have":[31],"not":[32],"demonstrated":[33],"meaningful":[34],"clinical":[35],"benefit":[36],"in":[37,62,75,267],"glioblastoma,":[38],"partly":[39],"because":[40],"tumor":[42,126],"microenvironment":[43],"immunosuppressive.":[45],"Preclinically,":[46],"TTFields":[47,80,148,177,186,262],"can":[48],"induce":[49],"immunogenic":[50],"cell":[51,64],"death":[52],"and":[53,66,87,114,189,198,231,240],"activate":[54],"type":[55],"1":[56],"interferon":[57],"signaling,":[58],"downstream":[60],"increases":[61],"dendritic":[63],"activation":[65],"cytotoxic":[67],"T-cell":[68],"infiltration.":[69],"In":[70],"a":[71,97],"phase":[72,101],"2":[73],"study":[74,103],"newly":[76,106,270],"diagnosed":[77,107,271],"(NCT03405792),":[79],"plus":[81,153,263],"temozolomide/pembrolizumab":[82,264],"improved":[83],"progression-free":[84],"(PFS)":[86],"OS":[88,212,266],"compared":[89],"historical":[91],"controls.":[92],"Methods":[93],"EF-41/KEYNOTE":[94,256],"D58":[95,257],"randomized,":[98],"double-blind,":[99],"placebo-controlled":[100],"3":[102],"(NCT06556563).":[104],"Eligibility:":[105],"(WHO":[109],"2021":[110],"Classification);":[111],"completed":[112],"chemoradiotherapy":[113],"able":[115],"to":[116,147,210],"initiate":[117],"treatment":[118],"4\u20137":[119],"weeks":[120,239],"thereafter;":[121],"ECOG":[122],"performance":[123],"status":[124],"0\u20131;":[125],"tissue":[127],"central":[129],"MGMT":[130],"methylation":[131],"analysis;":[132],"no":[133],"prior":[134],"anti-PD(L)1":[135],"or":[136,175],"anti-PDL2":[137],"therapy;":[138],"ongoing":[139],"dexamethasone":[140],"\u22642":[141],"mg/day.":[142],"Patients":[143],"are":[144,235,247],"randomized":[145],"2:1":[146],"(200":[149],"kHz,":[150],"\u226518":[151],"hours/day)":[152],"temozolomide":[155],"(150-200":[156],"mg/m2/day":[157],"PO,":[158],"days":[159,162],"1-5":[160],"Q28":[161],"6\u201312":[164],"cycles)":[165,174],"either":[167],"pembrolizumab":[168],"200":[169],"mg":[170],"IV":[171],"Q3W":[172],"(\u226435":[173],"placebo.":[176],"continued":[179],"until":[180],"second":[181],"progression.":[182],"At":[183],"first":[184],"progression,":[185],"maintained":[188],"patients":[190,268],"may":[191],"receive":[192],"salvage":[193],"therapy,":[194],"including":[195],"re-resection,":[196],"systemic":[199],"therapy.":[200],"Results":[201],"Target":[202],"enrollment":[203],"741":[205],"patients,":[206],"providing":[207],"85%":[208],"power":[209],"detect":[211],"improvement":[213],"(two-sided":[214],"alpha":[215],"0.05,":[216],"2-sided":[217],"log-rank":[218],"test).":[219],"Primary":[220],"endpoint:":[221],"OS.":[222],"Secondary":[223],"endpoints":[224],"include":[225],"PFS,":[226],"PFS2,":[227],"quality":[228],"of":[229],"life,":[230],"safety.":[232],"MRI":[233],"assessments":[234],"performed":[236],"every":[237],"9":[238],"evaluated":[241],"per":[242],"RANO":[243],"2.0.":[244],"Adverse":[245],"events":[246],"monitored":[248],"throughout":[249],"study.":[251],"Enrollment":[252],"ongoing.":[254],"Conclusions":[255],"will":[258],"determine":[259],"whether":[260],"improve":[265],"glioblastoma.":[272]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2026-08-28T00:00:00"}